<DOC>
	<DOCNO>NCT01515956</DOCNO>
	<brief_summary>This open-label Phase 2 study evaluate safety efficacy weekly 2.0 mg/kg/wk infusion BMN 110 pediatric patient , less 5 year age time administration first dose study drug , diagnose MPS IVA ( Morquio A Syndrome ) 208 week .</brief_summary>
	<brief_title>Study BMN 110 Pediatric Patients &lt; 5 Years Age With Mucopolysaccharidosis IVA ( Morquio A Syndrome )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<criteria>Less 5 year age time first study drug infusion Documented clinical diagnosis MPS IVA base clinical sign symptom MPS IVA document reduce fibroblast leukocyte GALNS enzyme activity genetic test confirm diagnosis MPS IVA Written inform consent provide parent legally authorize representative nature study explain prior researchrelated procedure . Previous hematopoietic stem cell transplant ( HSCT ) . Previous treatment BMN 110 . Known hypersensitivity component BMN 110 . Major surgery within 3 month prior stuy entry plan major surgery 52week treatment period . Use investigational product investigational medical device within 30 day prior Screening , requirement investigational agent prior completion schedule study assessment . Concurrent disease condition , include limited symptomatic cervical spine instability , clinically significant spinal cord compression , severe cardiac disease would interfere study participation safety determine Investigator . Any condition , view Investigator , place patient high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Mucopolysaccharidosis IVA type A</keyword>
	<keyword>MPS IVA Type A</keyword>
	<keyword>Mucopolysaccharidosis IVA</keyword>
	<keyword>MPS IVA</keyword>
	<keyword>Morquio A Syndrome</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>LSD</keyword>
	<keyword>N-acetylgalactosamine-6-sulfatase</keyword>
	<keyword>N-acetylgalactosamine-6-sulfate</keyword>
	<keyword>sulfatase</keyword>
	<keyword>galactose-6-sulfatase</keyword>
	<keyword>GALNS</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>ERT</keyword>
</DOC>